This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Pachamuthu Kandasamy, PhD
Vice President, Medicinal Chemistry at Wave Life Sciences
Speaker

Profile

Dr. Kandasamy has over 15 years of experience in oligonucleotide research and development. His work is dedicated to novel chemical modification on oligonucleotides to improve pharmacological properties. He worked on siRNA delivery technologies and contributed to three approved drugs at Alnylam prior to joining Wave Life Sciences in 2016. He earned a Ph.D. in synthetic carbohydrate chemistry focused on discovering new methods for stereospecific anomeric C-O and C-C bond formation related to GalNAc sugars from the Indian Institute of Technology Kanpur (India) before completing postdoctoral work on glycopeptides at the University of Konstanz (Germany) with Professor Richard R. Schmidt and worked on aminoglycosides antibiotics at University of Montreal (Canada) with Professor Stephan Hanessian.

Agenda Sessions

  • Strategies for the Characterization of Stereopure Chimeric PO/PS/PN Oligonucleotides

    9:00am